Skip to main content

Main menu

  • About
    • Our Mission
    • Donors
    • Board of Directors
    • Advisory Boards
    • Staff
    • Careers
    • FAQ
    • Annual Report
  • Why New TB Drugs?
    • Global Pandemic
    • Inadequate Treatment
    • Antimicrobial Resistance
    • Maternal and Child Health
    • Cycle of Poverty
  • R&D
    • Scientific Vision
    • Pipeline
    • Discovery
    • Engaging Communities
  • Access
    • Our Commitment
    • Access in TB Market
    • Child-friendly medicines
    • Pretomanid and BPaL
    • Pathways to Access BPaL
  • News
    • Latest News
    • Publications
    • Voices of TB
    • Research Papers
    • Making an Impact
  • Donate

Search form

Our Pipeline

  • Portfolio
  • Compounds
  • Regimens
  • Partners
  • Trials
Clinical Development

Discovery

TB Alliance manages the largest pipeline of new TB drugs in history. Projects with the potential to have the greatest impact on the disease, while being cost-effective and simple to administer, are prioritized.

Lead Identification

  • PptTEvotec, Texas A&M University, Weill Cornel Medical, University of North Carolina
  • Intracellular Active Series Evotec
  • Malate Synthetase InhibitorsTexas A&M University
  • PantothenamideTropIQ, Weill Cornel Medical
  • GHIT Hit-to-Lead ProgramsTakeda Pharmaceuticals, University of Illinois at Chicago, Daiichi Sankyo RD Novare, Chugai, Astellas
  • GHIT Hit Identification ProgramsDaiichi Sankyo RD Novare
  • Clp Lead Identification ProgramsUniversity of Illinois at Chicago, Texas A&M University, Harvard University, Center of Excellence in Translational Research (CETR)
  • PknBSchrodinger, University of Auckland
  • Whole Cell Hit-to-Lead ProgramGlaxoSmithKline

Lead Optimization

  • ClpC1University of Illinois at Chicago, Harvard University, Center of Excellence in Translational Research (CETR)
  • Anti-TB Natural ProductsEvotec
  • Intracellular Active SeriesGlaxoSmithKline
  • KasAGlaxoSmithKline
  • MmpL3 InhibitorsAbbVie, ERA4TB
  • RNA Polymerase InhibitorsCenter of Excellence in Translational Research (CETR)
  • InhA InhibitorsGlobal Health Drug Discovery Institute

Preclinical Development

  • PAN-TB CollaborationBill & Melinda Gates Medical Research Institute
  • Preclinical TB Regimen DevelopmentJohns Hopkins University

Navigate

  • About
  • Why New TB Drugs?
  • R&D
  • Access
  • News
  • Donate

New York: 80 Pine Street, 20th floor, New York, NY 10005 • +1 212 227 7540

Pretoria: Boardwalk Office Park, Block 1/Suite 5, 107 Haymeadow Street, Faerie Glen, Pretoria 0043, South Africa • +27 12 991 6328

Visit our South Africa website
Press Inquiries

Thomas Lynch
p | +1 646 616 8639
e | thomas.lynch@tballiance.org

Jobs

View job openings

Join our mailing list
Interests
© 2023 The TB Alliance. All Rights Reserved. Site by Darby Communications Report a Concern